Croda International Plc stock (GB00BJFFLV09): Analysts see modest upside after recent share moves and Q1 update

Croda International Plc shares have edged higher in recent sessions as analysts maintain a broadly positive stance and the specialty chemicals group reports stable Q1 trading.

Croda International Plc shares have moved modestly higher in recent trading as analysts continue to see limited upside potential and the specialty chemicals group reports stable first?quarter performance. The stock trades around 2,830 pence on the London Stock Exchange, with analysts citing a consensus target in the low?3,000 pence range, implying a single?digit percentage gain over the next 12 months MarketBeat as of 10/24/2025.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Croda International Plc
• Sector/industry: Specialty chemicals
• Headquarters/country: United Kingdom
• Core markets: Europe, North America, Asia, Middle East, Africa, Latin America
• Key revenue drivers: Consumer care, life sciences, industrial specialties
• Home exchange/listing venue: London Stock Exchange (LSE: CRDA)
• Trading currency: GBP

Croda International Plc: core business model

Croda International Plc operates as a global specialty chemicals company, supplying ingredients and solutions to consumer care, life sciences and industrial specialty markets. The group focuses on high?value, performance?driven products such as emulsifiers, surfactants and functional ingredients used in personal care, pharmaceuticals, crop protection and industrial applications Croda Investor Relations as of 2026.

The company’s business model emphasizes innovation, long?term customer partnerships and geographic diversification. Croda targets markets where technical expertise and regulatory know?how create barriers to entry, allowing it to maintain relatively stable margins even in cyclical environments. Its operations span Europe, the Middle East, Africa, North America, Asia and Latin America, giving it exposure to both developed and emerging economies Simply Wall St as of 2026.

Main revenue and product drivers for Croda International Plc

Croda’s revenue is driven by three main segments: consumer care, life sciences and industrial specialties. In 2025, the group reported around £1.7 billion in sales, with mid?single?digit growth and adjusted operating profit up nearly 8% at constant currency, reflecting pricing discipline and volume gains in certain end markets DirectorsTalk Interviews as of 2026.

Consumer care remains a key pillar, supplying ingredients for skincare, haircare and other personal?care products. Life sciences include pharmaceutical excipients and crop?protection ingredients, while industrial specialties cover lubricants, coatings and other performance chemicals. This mix helps Croda balance exposure to consumer demand, healthcare spending and industrial activity, which is relevant for US investors given the group’s presence in North America and its role in global supply chains Croda Investor Relations as of 2026.

Why Croda International Plc matters for US investors

US investors encounter Croda International Plc through its London listing and via over?the?counter channels, with the group’s products embedded in consumer and industrial value chains that touch the United States. The company’s exposure to North America and its participation in global specialty?chemicals markets mean its performance can reflect trends in US consumer spending, healthcare and manufacturing Simply Wall St as of 2026.

For US?based portfolios, Croda offers a way to gain indirect exposure to specialty?chemicals growth without direct ownership of a US?listed peer. Its relatively high dividend yield and stable cash flows may appeal to income?oriented investors, while its innovation?driven model aligns with themes such as premiumization in personal care and demand for advanced materials in life sciences AJ Bell as of 05/05/2026.

Analyst views and recent price action

Analysts covering Croda International Plc generally maintain a moderate?buy or hold stance, with consensus 12?month targets clustered around 3,100–3,300 pence per share. Over the past 90 days, several banks have reiterated or adjusted their ratings, including Jefferies, Morgan Stanley and Deutsche Bank, reflecting a cautious but constructive outlook MarketBeat as of 10/24/2025.

Recent trading has seen the stock hover near 2,830 pence, with a trailing?12?month total return slightly below the FTSE 100 benchmark. The shares trade at a premium valuation, with a price?to?earnings ratio above 60, which underscores the market’s expectation of continued earnings growth and resilience in Croda’s end markets AJ Bell as of 05/05/2026.

Conclusion

Croda International Plc continues to report stable trading, supported by growth in consumer care and disciplined cost management across its life sciences and industrial specialties segments. Analysts see only modest upside from current levels, reflecting the stock’s already elevated valuation and the challenges of sustaining high earnings growth in a competitive specialty?chemicals landscape MarketBeat as of 10/24/2025.

For US investors, the company offers indirect exposure to global specialty?chemicals demand and a relatively high dividend yield, but its London?listed structure and premium valuation mean it may suit only those comfortable with foreign?exchange risk and higher?multiple equities. As with any stock, investors should weigh Croda’s growth prospects against its valuation, sector risks and broader macroeconomic conditions before making decisions Croda Investor Relations as of 2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.